Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study

Parhofer, Klaus G.; Pittrow, David; Birkenfeld, Andreas L.; Fraass, Uwe; Hohenstein, Bernd; Siegert, Carsten; Klotsche, Jens; Steinhagen-Thiessen, Elisabeth; Dexl, Stefan; Schettler, Volker J. J.; Laufs, Ulrich

dc.contributor.author	Birkenfeld, Andreas L.
dc.date.accessioned	2025-09-30T06:32:45Z
dc.date.available	2025-09-30T06:32:45Z
dc.date.issued	2025
dc.identifier.issn	0001-5385
dc.identifier.uri	http://hdl.handle.net/10900/170391
dc.language.iso	en	de_DE
dc.publisher	Abingdon : Taylor & Francis Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1080/00015385.2025.2490381	de_DE
dc.subject.ddc	610	de_DE
dc.title	Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250630000000_00866
utue.publikation.seiten	475-486	de_DE
utue.personen.roh	Parhofer, Klaus G.
utue.personen.roh	Pittrow, David
utue.personen.roh	Birkenfeld, Andreas L.
utue.personen.roh	Fraass, Uwe
utue.personen.roh	Hohenstein, Bernd
utue.personen.roh	Siegert, Carsten
utue.personen.roh	Klotsche, Jens
utue.personen.roh	Steinhagen-Thiessen, Elisabeth
utue.personen.roh	Dexl, Stefan
utue.personen.roh	Schettler, Volker J. J.
utue.personen.roh	Laufs, Ulrich
dcterms.isPartOf.ZSTitelID	Acta Cardiologica	de_DE
dcterms.isPartOf.ZS-Issue	5	de_DE
dcterms.isPartOf.ZS-Volume	80	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE